Cyclacel Stock Buy Hold or Sell Recommendation

CYCC
 Stock
  

USD 0.83  0.04  4.60%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cyclacel Pharmaceuticals is 'Strong Sell'. Macroaxis provides Cyclacel Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CYCC positions. The advice algorithm takes into account all of Cyclacel Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from Cyclacel Pharmaceuticals' buy-and-hold perspective. Continue to Cyclacel Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Cyclacel and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Cyclacel Pharmaceuticals.

Execute Cyclacel Pharmaceuticals Buy or Sell Advice

The Cyclacel recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cyclacel Pharmaceuticals. Macroaxis does not own or have any residual interests in Cyclacel Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cyclacel Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Cyclacel PharmaceuticalsBuy Cyclacel Pharmaceuticals
Strong Sell

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Details

Reporting Quality (M-Score)

Details
For the selected time horizon Cyclacel Pharmaceuticals has a Mean Deviation of 3.87, Standard Deviation of 5.1 and Variance of 26.04
We provide trade advice to complement the prevailing expert consensus on Cyclacel Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Cyclacel Pharmaceuticals is not overpriced, please confirm all Cyclacel Pharmaceuticals fundamentals, including its gross profit, debt to equity, and the relationship between the price to earning and cash and equivalents . As Cyclacel Pharmaceuticals appears to be a penny stock we also recommend to validate its price to book numbers.

Cyclacel Pharmaceuticals Trading Alerts and Improvement Suggestions

Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days
Cyclacel Pharmaceuticals has high historical volatility and very poor performance
Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock
Net Loss for the year was (18.89 M) with loss before overhead, payroll, taxes, and interest of (338 K).
Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (18.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Cyclacel Pharmaceuticals Returns Distribution Density

The distribution of Cyclacel Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Cyclacel Pharmaceuticals' future price movements. The chart of the probability distribution of Cyclacel Pharmaceuticals stock daily returns describes the distribution of returns around its average expected value. We use Cyclacel Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cyclacel Pharmaceuticals returns is essential to provide solid investment advice for Cyclacel Pharmaceuticals.
Mean Return-0.87Value At Risk-7.52
Potential Upside9.02Standard Deviation5.10
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cyclacel Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Cyclacel Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cyclacel Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclacel Pharmaceuticals backward and forwards among themselves. Cyclacel Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cyclacel Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wolverine Trading LlcCall Options12.2 K16 K
Wolverine Asset Management LlcCommon Shares24.9 KK
Wolverine Asset Management LlcCommon Shares24.9 K12 K
Wfg Advisors LpCommon Shares416K
Wfg Advisors LpCommon Shares416K
Wfg Advisors LpCommon Shares416K
Wfg Advisors LpCommon Shares416K
Wells Fargo CompanyCommon Shares5721000
Note, although Cyclacel Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cyclacel Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cyclacel Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cyclacel Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cyclacel stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
-0.92
β
Beta against NYSE Composite0.42
σ
Overall volatility
5.03
Ir
Information ratio -0.19

Cyclacel Pharmaceuticals Volatility Alert

Cyclacel Pharmaceuticals exhibits very low volatility with skewness of 0.65 and kurtosis of 0.41. However, we advise investors to further study Cyclacel Pharmaceuticals technical indicators to ensure that all market info is available and is reliable. Cyclacel Pharmaceuticals is a potential penny stock. Although Cyclacel Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cyclacel Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cyclacel instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Cyclacel Pharmaceuticals Fundamentals Vs Peers

Comparing Cyclacel Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cyclacel Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Cyclacel Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cyclacel Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cyclacel Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cyclacel Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Cyclacel Pharmaceuticals to competition
FundamentalsCyclacel PharmaceuticalsPeer Average
Return On Equity(0.60) %(0.31) %
Return On Asset(0.42) %(0.14) %
Current Valuation(13.12 M)16.62 B
Shares Outstanding12.54 M571.82 M
Shares Owned by Insiders3.67 %10.09 %
Shares Owned by Institutions33.44 %39.21 %
Number of Shares Shorted446.5 K4.71 M
Price to Earning(0.40) X28.72 X
Price to Book0.39 X9.51 X
Price to Sales74.57 X11.42 X
Gross Profit(338 K)27.38 B
EBITDA(15 M)3.9 B
Net Income(18.89 M)570.98 M
Cash and Equivalents29.08 M2.7 B
Cash per Share2.32 X5.01 X
Total Debt113 K5.32 B
Debt to Equity0.003 %48.70 %
Current Ratio6.38 X2.16 X
Book Value Per Share1.76 X1.93 K
Cash Flow from Operations(18.54 M)971.22 M
Short Ratio4.24 X4.00 X
Earnings Per Share(2.05) X3.12 X
Target Price18.0
Beta1.13-0.15
Market Capitalization9.65 M19.03 B
Total Asset42.59 M29.47 B
Retained Earnings(385.86 M)9.33 B
Working Capital18.81 M1.48 B
Current Asset24.57 M9.34 B
Current Liabilities5.75 M7.9 B
Z Score19.58.72
Net Asset42.59 M
   Acquisition by Gregory Hradsky of 2000 shares of Cyclacel Pharmaceuti subject to Rule 16b-3 [view details]

About Cyclacel Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Cyclacel Pharmaceuticals? Buying financial instruments such as Cyclacel Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Cyclacel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Picks Thematic Idea Now

Macroaxis Picks
Macroaxis Picks Theme
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
View All  Next Launch
Continue to Cyclacel Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
9.6 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.